TP53 and cancer: The progress seen in targeting the p53 mutant Y220C with small molecules, along with their structural information and successful rescuing of wt-like functionality, provides the proof of concept and a tremendous opportunity to develop a new class of anticancer drugs for this mutant, which has a high rate of incidence in human cancers.